Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia

American Journal of Psychiatry

Volumn 160, Issue 6, 2003, Pages 1100-1109

  Clinton, Sarah M ^a   Haroutunian, Vahram ^b   Davis, Kenneth L ^b   Meador Woodruff, James H ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; MEMBRANE PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POSTSYNAPTIC DENSITY PROTEIN 95; POSTSYNAPTIC RECEPTOR; PROTEIN SUBUNIT; SCAFFOLD PROTEIN; DLG3 PROTEIN, HUMAN; DLG4 PROTEIN, HUMAN; NERVE PROTEIN; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN L; NEUROPEPTIDE; NR1 NMDA RECEPTOR; NUCLEAR PROTEIN; POSTSYNAPTIC DENSITY PROTEINS; SAPAP PROTEINS; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR;

ARTICLE; HUMAN; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; SYNAPTIC MEMBRANE; THALAMUS; AGED; COMPARATIVE STUDY; EXON; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETICS; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AGED; EXONS; FEMALE; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; NEUROFILAMENT PROTEINS; NEUROPEPTIDES; NUCLEAR PROTEINS; PROTEIN ISOFORMS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; THALAMUS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0038488293     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.6.1100     Document Type: Article

References (61)

1. Jones EG: Cortical development and thalamic pathology in schizophrenia. Schizophr Bull 1997; 23:483-501
2. Andreasen NC, Paradiso S, O'Leary DS: "Cognitive dysmetria" as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical- cerebellar circuitry? Schizophr Bull 1998; 24:203-218
3. Andreasen NC, O'Leary DS, Cizadlo T, Arndt S, Rezai K, Boles Ponto LL, Watkins GL, Hichwa RD: Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic- cerebellar circuitry. Proc Natl Acad Sci USA 1996; 93:9985-9990
4. Andreasen NC, Arndt S, Swayze V II, Cizadlo T, Flaum M, O'Leary D, Ehrhardt JC, Yuh WTC: Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 1994; 266:294-298
5. Buchsbaum MS, Someya T, Teng CY, Abel L, Chin S, Najafi A, Haier RJ, Wu J, Bunney WE Jr: PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatry 1996; 153:191-199
6. Gilbert AR, Rosenberg DR, Harenski K, Spencer S, Sweeney JA, Keshavan MS: Thalamic volumes in patients with first-episode schizophrenia. Am J Psychiatry 2001; 158:618-624
7. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC: Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 1998; 155:1711-1717
8. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT: Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992; 49:522-530
9. Hazlett EA, Buchsbaum MS, Byne W, Wei T-C, Spiegel-Cohen J, Geneve C, Kinderlehrer R, Haznedar MM, Shihabuddin L, Siever LJ: Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am J Psychiatry 1999; 156:1190-1199
10. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, Seaward J, McKenna P, Chua SE, Schnorr L, et al: A functional neuroanatomy of hallucinations in schizophrenia. Nature 1995; 378:176-179
11. Byne W, Buchsbaum MS, Kemether E, Hazlett EA, Shinwari A, Mitropoulou V, Siever LJ: Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder. Arch Gen Psychiatry 2001; 58:133-140
12. Pakkenberg B: Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry 1990; 47:1023-1028
13. Popken GJ, Bunney WE Jr, Potkin SG, Jones EG: Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. Proc Natl Acad Sci USA 2000; 97:9276-9280
14. Danos P, Baumann B, Bernstein HG, Franz M, Stauch R, Northoff G, Krell D, Falkai P, Bogerts B: Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons. Psychiatry Res 1998; 82:1-10
15. Ibrahim HM, Hogg AJ Jr, Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH: Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 2000; 157:1811-1823
16. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH: Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry 2001; 158:1393-1399
17. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH: Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. Neuroreport 2001; 12:2885-2887
18. Popken GJ, Leggio MG, Bunney WE, Jones EG: Expression of mRNAs related to the GABAergic and glutamatergic neurotransmitter systems in the human thalamus: normal and schizophrenic. Thalamus & Related Systems 2002; 1:349-369
19. Meador-Woodruff JH, Healy DJ: Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 2000; 31:288-294
20. Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158:1367-1377
21. Lahti A, Holcomb H, Medoff D, Tamminga C: Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6:869-872
22. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP: Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994; 151:1234-1236
23. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney WE Jr, Jones EG: Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996; 16:19-30
24. Dracheva S, Marras SAE, Elhakem SL, Kramer FR, Davis KL, Haroutunian V: N-Methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 2001; 158:1400-1410; correction, 158:2107
25. Dean B, Scarr E, Bradbury R, Copolov D: Decreased hippocampal (CA3) NMDA receptors in schizophrenia. Synapse 1999; 32:67-69
26. Grimwood S, Slater P, Deakin JF, Hutson PH: NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. Neuroreport 1999; 10:461-465
27. Le Corre S, Harper CG, Lopez P, Ward P, Catts S: Increased levels of expression of an NMDARI splice variant in the superior temporal gyrus in schizophrenia. Neuroreport 2000; 11:983-986
28. Gao X-M, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA: Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 2000; 157:1141-1149
29. Hollmann M, Heinemann S: Cloned glutamate receptors. Annu Rev Neurosci 1994; 17:31-108
30. Das S, Sasaki YF, Rothe T, Premkumar LS, Takasu M, Crandall JE, Dikkes P, Conner DA, Rayudu PV, Cheung W, Chen HS, Lipton SA, Nakanishi N: Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature 1998; 393:377-381
31. Zukin R, Bennett M: Alternatively spliced isoforms of the NMDARI receptor subunit. Trends Neurosci 1995; 18:306-313
32. Sheng M, Cummings J, Roldan L, Jan Y, Jan L: Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature 1994; 368:144-147
33. Tingley W, Roche K, Thompson A, Huganir R: Regulation of NMDA receptor phosphorylation by alternative splicing of the C-terminal domain. Nature 1993; 364:70-73
34. Ehlers M, Zhang S, Bernhadt J, Huganir R: Inactivation of NMDA receptors by direct interaction of calmodulin with the NR1 subunit. Cell 1996; 84:745-755
35. Brenman J, Christopherson K, Craven S, McGee A, Bredt D: Cloning and characterization of postsynaptic density 93, a nitric oxide synthase interacting protein. J Neurosci 1996; 16:7407-7415
36. Lau L, Mammen A, Ehlers M, Kindler S, Chung W, Garner C, Huganir R: Interaction of the N-methyl-D-aspartate receptor complex with a novel synapse-associated protein, SAP102. J Biol Chem 1996; 271:21622-21628
37. Rutter A, Stephenson F: Coexpression of postsynaptic density-95 protein with NMDA receptors results in enhanced receptor expression together with a decreased sensitivity to L-glutamate. J Neurochem 2000; 75:2501-2510
38. Sheng M, Pak D: Ligand-gated ion channel interactions with cytoskeletal and signaling proteins. Annu Rev Physiol 2000; 62:755-778
39. Ohnuma T, Kato H, Arai H, Faull R, McKenna P, Emson P: Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. Neuroreport 2000; 11:3133-3137
40. Clinton SM, Meador-Woodruff JH: Nucleus-specific expression of NMDA receptor-associated postsynaptic density proteins in primate thalamus. Thalamus & Related Systems 2002; 1:303-316
41. Meador-Woodruff JH, Mansour A, Bunzow JR, Van Tol HH, Watson SJ Jr, Civelli O: Distribution of D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci USA 1989; 86:7625-7628
42. Miller JA: The calibration of 35S or 32P with 14C-labeled brain paste or 14C-plastic standards for quantitative autoradiography using LKB Ultrofilm or Amersham Hyperfilm. Neurosci Lett 1991; 121:211-214
43. Standaert DG, Testa CM, Young AB, Penney JB Jr: Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol 1994; 343:1-16
44. Meoni P, Bunnemann BH, Trist DG, Bowery NG: N-terminal splice variants of the NMDAR1 glutamate receptor subunit: differential expression in human and monkey brain. Neurosci Lett 1998; 249:45-48
45. Laurie DJ, Seeburg PH: Regional and developmental heterogeneity in splicing of the rat brain NMDAR1 mRNA. J Neurosci 1994; 14(5, part 2):3180-3194
46. Logan S, Rivera F, Leonard J: Protein kinase C modulation of recombinant NMDA receptor currents: roles for the C-terminal C1 exon and calcium ions. J Neurosci 1999; 19:974-986
47. Zheng X, Zhang L, Wang AP, Bennett MV, Zukin RS: Protein kinase C potentiation of N-methyl-D-aspartate receptor activity is not mediated by phosphorylation of N-methyl-D-aspartate receptor subunits. Proc Natl Acad Sci USA 1999; 96:15262-15267
48. Ehlers MD, Tingley WG, Huganir RL: Regulated subcellular distribution of the NR1 subunit of the NMDA receptor. Science 1995; 269:1734-1737
49. Okabe S, Miwa A, Okado H: Alternative splicing of the C-terminal domain regulates cell surface expression of the NMDA receptor NR1 subunit. J Neurosci 1999; 19:7781-7792
50. Standley S, Roche KW, McCallum J, Sans N, Wenthold RJ: PDZ domain suppression of an ER retention signal in NMDA receptor NR1 splice variants. Neuron 2000; 28:887-898
51. Scott DB, Blanpied TA, Swanson GT, Zhang C, Ehlers MD: An NMDA receptor ER retention signal regulated by phosphorylation and alternative splicing. J Neurosci 2001; 21:3063-3072
52. Migaud M, Charlesworth P, Dempster M, Webster LC, Watabe AM, Makhinson M, He Y, Ramsay MF, Morris RG, Morrison JH, O'Dell TJ, Grant SG: Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature 1998; 396:433-439
53. Ehlers M, Fung E, O'Brien R, Huganir R: Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments. J Neurosci 1998; 18:720-730
54. Lin J, Wyszynski M, Madhavan R, Sealock R, Kim J, Sheng M: Yotiao, a novel protein of neuromuscular junction and brain that interacts with specific splice variants of NMDA receptor subunit NR1. J Neurosci 1998; 18:2017-2027
55. Xu Z, Dong DL, Cleveland DW: Neuronal intermediate filaments: new progress on an old subject. Curr Opin Neurobiol 1994; 4:655-661
56. Shenolikar S: Protein serine/threonine phosphatases - new avenues for cell regulation. Annu Rev Cell Biol 1994; 10:55-86
57. Terry-Lorenzo R, Inoue M, Connor J, Haystead T, Armbruster B, Gupta R, Oliver C, Shenolikar S: Neurofilament-L is a protein phosphatase-1-binding protein associated with neuronal plasma membrane and post-synaptic density. J Biol Chem 2000; 275:2439-2446
58. Cohen BM, Wan W: The thalamus as a site of action of antipsychotic drugs. Am J Psychiatry 1996; 153:104-106
59. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA: Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 1996; 153:41-49
60. Deutch A, Ongur D, Duman R: Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: a novel antipsychotic drug action. Neuroscience 1995; 66:337-346
61. Ulas J, Nguyen L, Cotman C: Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex. Neuroreport 1993; 4:1049-1051